Ulla Olsson‐Strömberg

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

Alice Giustacchini, Supat Thongjuea, Nikolaos Barkas et al. · Nature Medicine · 2017 · 421 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +15

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums et al. · Leukemia · 2016 · 247 citations · Full text

Medicine, Hematology, Immunology +14

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Rebecca Warfvinge, Linda Geironson, Mikael N.E. Sommarin et al. · Blood · 2017 · 177 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +12

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Martin Höglund, Fredrik Sandin, Karin Hellström et al. · Blood · 2013 · 127 citations

Medicine, Oncology, Pharmacotherapy +13